Comparative Pharmacology
Head-to-head clinical analysis: EVKEEZA versus ZETIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVKEEZA versus ZETIA.
EVKEEZA vs ZETIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVKEEZA (evinacumab) is a recombinant human monoclonal antibody that binds to and inhibits angiopoietin-like 3 (ANGPTL3), a key regulator of lipoprotein metabolism. Inhibition of ANGPTL3 reduces levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, and other lipoproteins by enhancing the activity of lipoprotein lipase and endothelial lipase, leading to increased clearance of very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL). It also decreases hepatic very low-density lipoprotein production.
Ezetimibe selectively inhibits the intestinal absorption of cholesterol and related phytosterols by binding to the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border membrane of enterocytes.
Subcutaneous injection of 135 mg once every 2 weeks (every 14 days).
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of 16.8 days (range 10–24 days) in patients with homozygous familial hypercholesterolemia, supporting monthly subcutaneous dosing.
Terminal elimination half-life of ezetimibe is 22 hours; ezetimibe-glucuronide has a half-life of 30 hours, allowing once-daily dosing.
Eliminated primarily via reticuloendothelial system metabolism; renal excretion is minimal (<1% unchanged drug); fecal excretion of metabolites accounts for ~99%.
Primarily fecal (78-85%) with minimal renal excretion (approximately 1%).
Category C
Category C
Lipid-lowering Agent
Lipid-lowering Agent